Claims for Patent: 6,077,667

Summary for Patent: 6,077,667

Title:	Method for chromosomal rearrangement by consecutive gene targeting of two recombination substrates to the deletion endpoints
Abstract:	The present invention involves the creation of defined chromosomal deficiencies, inversions and duplications using Cre recombinase in ES cells transmitted into the mouse germ line. These chromosomal reconstructions can extend up to 3-4 cM. Chromosomal rearrangements are the major cause of inherited human disease and fetal loss. Additionally, translocations and deletions are recognized as major genetic changes that are causally involved in neoplasia. Chromosomal variants such as deletions and inversions are exploited commonly as genetic tools in organisms such as Drosophila. Mice with defined regions of segmental haploidy are useful for genetic screening and allow accurate models of human chromosomal diseases to be generated.
Inventor(s):	Bradley; Allan (Houston, TX), Ramirez-Solis; Ramiro (Missouri City, TX), Liu; Pentao (Fredrick, MD), Su; Hong (Houston, TX), Zheng; Binhai (Houston, TX)
Assignee:
Application Number:	08/883,616
Patent Claims:	1. A method for deleting a selected region of genetic material in cells comprising the steps of: inserting a first selection cassette at a 5' end of said selected region using conventional gene targeting methods, said first selection cassette comprising a first selectable marker, a first loxP recombination site, and a first portion of a second selectable marker; selecting cells expressing said first selectable marker; inserting a second selection cassette at a 3' end of said selected region using conventional gene targeting methods, said second selection cassette comprising a third selectable marker, a second loxP recombination site, and a remaining portion of said second selectable marker; expressing Cre recombinase to produce recombination between said first and second loxP sites; and selecting cells expressing said second selectable marker, wherein the selected region of genetic material is deleted. 2. The method of claim 1 wherein said first selectable marker is a puromycin resistance gene. 3. The method of claim 1 wherein said second selectable marker is a functional Hprt gene. 4. The method of claim 1 wherein said third selectable marker is a neomycin resistance gene. 5. The method of claim 1 wherein said first selectable marker is a puromycin resistance gene, said second selectable marker is an Hprt gene, and said third selectable marker is a neomycin resistance gene. 6. The method of claim 1 or 2 wherein said cells are embryonic stem cells. 7. The method of claim 1 or 2 wherein said cells are embryonic stem cells, and said cells are maintained as cell lines. 8. The method of claim 1 or 2 wherein said Cre is transiently expressed Cre. 9. The method of claim 1 or 2 wherein said Cre is inducibly expressed Cre. 10. The method of claim 1 or 2 wherein said Cre is constitutively expressed Cre. 11. A method of deleting a selected region of genetic material in cells comprising the steps of: inserting a first selection cassette at a 5' end of said selected region using either a conventional gene targeting vector or a viral vector, said first selection cassette comprising a first selectable marker, a first loxP recombination site, and a first portion of a second selectable marker; selecting cells expressing said first selectable marker; inserting a second selection cassette at a 3' end of said selected region using a conventional gene targeting vector or a viral vector, said second selection cassette comprising a third selectable marker, a second loxP recombination site, and a remaining portion of said second selectable marker; expressing transiently Cre recombinase to produce recombination between said first and second loxP sites; and selecting cells expressing said second selectable marker, wherein the selected region of genetic material is deleted. 12. The method of claim 11 wherein the viral vector is a retrovirus. 13. The method of claim 11 wherein the viral vector has a provirus structure comprising a cassette in turn comprising an hprt.DELTA.5' cassette, a loxP site, and a puromycin resistance gene. 14. The method of claim 11 wherein the viral vector has a provirus structure comprising a cassette in turn comprising an hprt.DELTA.5' cassette, a loxP site, and a neomycin resistance gene. 15. The method of claim 11 wherein the targeting or viral vectors are a first vector for inserting a first native sequence of DNA at said 5' end, comprising: a genomic insert cloned into the vector of about 7.5 kb; a tyrosinase minigene; a neomycin resistance gene; a 5' hprt fragment; and a loxP site in a hprt fragment intron; and a second vector for inserting a second native sequence of DNA at said 3' end, comprising: a genomic insert cloned into the vector of about 8.5 kb; a K14-agouti gene; a puromycin resistance gene; a 3' hprt fragment; and a loxp site embedded in a hprt fragment intron. 16. The method of claim 15 wherein said 3' hprt fragment has the following SEQ. ID. NO. 1 at the start of exon 3: GAC,TGA,ACG,TCT,TCG,AGA,TGT,GAT, GAA,GGA,GAT. 17. A replacement vector system comprising: a first vector for inserting a first native sequence of DNA at said 5' end, comprising: a genomic insert cloned into the vector of about 7.5 kb; a tyrosinase minigene; a neomycin resistance gene; a 5' hprt fragment; and a loxP site in a hprt fragment intron; and a second vector for inserting a second native sequence of DNA at said 3' end, comprising: a genomic insert cloned into the vector of about 8.5 kb; a K14-agouti gene; a puromycin resistance gene; a 3' hprt fragment; and a loxP site embedded in a hprt fragment intron. 18. The vector system of claim 17 wherein said 3' hprt fragment has the following sequence [SEQ. ID. NO. 1] at the start of exon 3: GAC,TGA,ACG,TCT,TCG,AGA, TGT,GAT,GAA,GGA,GAT. 19. A method for creating defined chromosomal deficiencies, deletions, and duplications comprising the steps of: identifying a desired region of a chromosome of interest to be deleted; inserting two native sequences at each endpoint of said region of said chromosome of interest using a first and a second targeting vector, each comprised of one or more selectable markers and a loxP site and an hprt fragment; transiently expressing Cre recombinase to produce recombination between each of two said loxP sites; whereby upon chromosomal rearrangement induced by said Cre recombinase, a functional Hprt expression cassette is reconstructed, wherein defined chromosomal deficiencies deletions and duplications are created.

Details for Patent 6,077,667

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2016-06-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2016-06-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2016-06-26